Announcements Trials
Browse Landscape

Status

Terminated 1Suspended 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Observational 3

Sponsor

Cancer Type

Dermatologic 12Genitourinary 5Thoracic 4Head & Neck 3Gastrointestinal 3Breast 3Other neoplasm 2Other solid neoplasm 1Other hematologic neoplasm 1CNS 1

Conditions

Breast Neoplasms 3

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Tomography, Optical Coherence × Breast × Clear all
NCT01506700 2019-07-26

Real Time Optical Coherence Tomography (OCT) of Human Tissue

Diagnostic Photonics, Inc.

Terminated
5 enrolled
Breast

Breast Neoplasms

NCT02313116 2019-07-18

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)

Diagnostic Photonics, Inc.

Suspended
50 enrolled
Breast

Breast Neoplasms

NCT01699867 2015-01-06

Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)

Diagnostic Photonics, Inc.

Completed
50 enrolled 5 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡